Time filter

Source Type

Guerra Mesa J.L.,Instituto Nacional Of Oncologia Y Radiobiologia | Vazquez Gonzalez J.M.,Instituto Nacional Of Oncologia Y Radiobiologia | Diaz Salas C.,Instituto Nacional Of Oncologia Y Radiobiologia | Perez Pena L.,Instituto Nacional Of Oncologia Y Radiobiologia | Naranjo Hernandez D.,Instituto Nacional Of Gastroenterologia
Revista Cubana de Cirugia | Year: 2010

Introduction: Proctosigmoidectomy with total mesorectum resection, reservoir in J and colorectal is useful in patients with low and middle rectum cancer, to avoid the definite terminal colostomy. The aim of present paper was to analyze the feasibility of such surgical technique, the multidisciplinary integral treatment and the results obtained. Methods: Fifteen patients were studied suffering of low and middle adenocarcinoma treated between January, 1996 and December, 2002 in Splanchnic Surgery Service of National Institute of Oncology and Radiobiology of La Habana City. Treatment included a combination of radiotherapy plus neocoadjuvant concurrent chemotherapy, followed by adjuvant chemotherapy and surgery. Results: Mean age of patients was of 56 years. The adenocarcinoma was the histological type diagnosed in all patients. Tumor staging the following: T1 and T2, in four patients (27%, respectively); T3 in seven patients (46%). Four patients (20%) had complications due to radiation treatment and five (33,3%), by surgical treatment. Surgical mortality occurred in one patient (6,6%) and eleven patients (73,3%) survived over 5 years. Neither patient had pelvic tumor relapse or by colorectal anastomosis. There was good sphincter continence. Conclusions: Total mesorectum resection and colorectal anastomosis with a colonic reservoir in J prevent the definite terminal colostomy, to cure a high percentage of patients with low and middle rectum cancer without respecting the oncology surgery principles, is well accepted by patients and it is feasible in our practice.

Rodriguez Y.A.S.,Institute Gastroenterologia | Soler E.A.,Institute Gastroenterologia | Oramas B.G.,Instituto Nacional Of Gastroenterologia
Revista Cubana de Medicina | Year: 2010

The hepatitis C virus becomes in leading cause of chronic hepatitis, hepatic cirrhosis, hepatocarcinoma and liver transplant at world level. OBJECTIVE: The aim of present study is to determine the virological, biochemical and histological course of patients presenting with Chronic hepatitis C under a combination of recombinant Interferon alfa-2b plus Ribavirin and to identify the main factors associated with the rates obtained of virological response. METHODS: A non-controlled and multicenter phase IV clinical-therapeutical trial was sponsored by the Institute of Gastroenterology and the Genetics and Biotechnology Engineering Center from May, 2002 to May, 2006. Sample included 122 patients diagnosed with chronic hepatitis C fulfilling the predetermined inclusion and exclusion criteria. Recombinant Interferon alfa-2b (3 millions of t.i.d units) was used plus Ribavirin (1000 or 1200 mg daily depending on the body weight) during 48 weeks. RESULTS: We achieved a sustained biochemical and virological response rate of 32.8 and 50.8%, respectively at week 72. A 41.3,% from the total of patients had a histological improvement at the expense of reduction of fibrosis and a few changes in inflammation level. CONCLUSIONS: Raking into account the global response rate achieved this combined treatment was considered effectiveness for chronic hepatitis C and we recommended to deepen in the knowledge of infection in Cuba, as well as in more efficient treatment options for this disease.

Sanchez M.C.A.,Instituto Nacional Of Nefrologia Abelardo Buch Lopez | Villanueva V.E.,Hospital General Docente Julio Trigo Lopez | Vazquez R.A.,Instituto Nacional Of Gastroenterologia
Revista Cubana de Investigaciones Biomedicas | Year: 2012

A double-blind, randomized, placebo-controlled, parallel group phase III clinical trial was conducted with the purpose of evaluating the effectiveness and safety of Renalof to remove and/or reduce calcium lithiasis in patients with calcium urolithiasis. The patients chosen were aged 18-65 and had stones smaller than 10 mm. These patients were treated with a natural product manufactured by the Spanish laboratory Catálisis SA, in a dosage of 1 capsule 3 times a day during 3 months, and monthly clinical, radiological, tomographic and echographic follow-up to record adverse effects. The main evaluation criterion was the size and number of the calculi, with favorable response when they either disappeared or their size was reduced. 110 patients were randomized to Renalof (n= 52) and placebo (n= 58). Stone size reduction was 7.7 % for the Renalof group and 0 % for the placebo group by the third month, whereas the stone disappearance response was 86.5 % by the third month for the Renalof group. The mean number of colics decreased by the third month, with only 0.4 ± 1.3 for the Renalof group. It was concluded that Renalof is an efficient product for the destruction or reduction of calcium renoureteral calculi, with no adverse effects.

Duran D.H.,Hospital Ginecobstetrico Ramon Gonzalez Coro | Mitjans O.D.,Hospital Ginecobstetrico Ramon Gonzalez Coro | del Rosario Abreu Vazquez M.,Instituto Nacional Of Gastroenterologia
Revista Cubana de Obstetricia y Ginecologia | Year: 2012

Introduction: In past years the conservative surgery became consolidated as a valid procedure in treatment of a determined group of breast cancer patients, thus allows to achieve a satisfactory local control with a lesser level of mutilation, neither modifying the survival nor distant metastasis index from a distance. Objective: To determine the results of conservative surgery of breast cancer according to the variables selected during 1991-2009. Methods: a longitudinal and retrospective study was conducted in women diagnosed and treated due to breast cancer who underwent conservative surgery (n= 77), fulfilling the established inclusion and exclusion criteria. Data descriptive analysis was performed by absolute and relative frequency distribution. The estimation of global survival curves and free of relapse was performed by Kaplan- Meier method. Results: The 40 to 59 age group was the predominant one for a 67.6 %. Only the 10.4% of patients had first line positive backgrounds of breast cancer. The IIA clinical stage predominates with a 54.5 % and the more frequent histological type, the infiltrating ductal carcinoma for a 84.4 %. The 5-years global survival for our patients was of 95 % and the interval free relapse was of 87.5 %. Conclusions: Our results not differ from those found in studies at world level.

Arrebola Y.M.,Instituto Nacional Of Gastroenterologia | Arrebola Y.M.,University of Habana | Gomez H.,Autonomous University of Barcelona | Valiente P.A.,University of Habana | And 2 more authors.
Biotecnologia Aplicada | Year: 2014

Dipeptidyl peptidase IV (DPP-IV, EC, also known as CD26, is a serine aminopeptidase that preferentially cleaves Xaa-Pro or Xaa-Ala dipeptides from the N-terminus of oligopeptides and processes regulatory peptides in vivo, leading to their biological activation or inactivation. The ezyme is a homodimer and each subunit is formed by a αβ-hydrolase domain and a β-propeller domain, involved in the enzymatic activity and its interaction with other proteins. It has an important role in multiple physiological functions, including the regulation of glucose metabolism being one of the current targets for the treatment of type II diabetes mellitus. This enzyme also regulates immune system responses mediated by CD4+ T lymphocytes, and recently has been identified a high/low DPP-IV activity regarding physiological levels, in pathologies like thyroid, ovarian, lung, skin, prostate cancers and central nervous system tumors. For these reasons this enzyme evolves as a new target of attention for the development of more efficient diagnostics being considering as molecular markers for some pathologies and target for the development of new therapeutic assessments in cancer. Current research interests are focused in depth in the structure-function relation for this enzyme, as a key point for the development of new therapies in pathologies involving DPP-IV activity or its interaction with other proteins.

Discover hidden collaborations